Conleth M.
- Country
- Ireland
- Department
- Bon Secours Cork Cancer Centre, Clinical Trials
Research Overview
- A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer
- A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)
- Phase 3 Randomized Study of Pembrolizumab Versus Platinum-Based Chemotherapy in Mismatch Repair Deficient Advanced or Recurrent Endometrial Carcinoma
Data & Insights
Has run more than one trial at 161 of 385 partner sites.
Specializations
Breast Cancer Expertise
Specializes in multiple breast cancer subtypes, with particular focus on triple negative breast cancer (TNBC) and hormone receptor-positive/HER2-negative breast cancer. Investigates innovative therapeutic approaches in both early-stage and metastatic settings.
- Neoadjuvant and adjuvant therapy combinations
- Endocrine therapy optimization
- Novel therapeutic combinations with immunotherapy
Gynecologic Oncology
Conducts research in advanced ovarian cancer and endometrial carcinoma, with expertise in treating various gynecologic malignancies including fallopian tube and peritoneal cancers.
- Platinum-sensitive recurrent disease
- Targeted therapies for folate receptor-alpha expression
- Maintenance treatment strategies
Precision Medicine
Focuses on biomarker-driven treatment approaches and personalized therapy selection across multiple cancer types, including studies of targeted therapies for specific molecular profiles.
- HRR mutation and HRD-positive cancers
- Receptor expression-guided therapies
- Novel therapeutic combinations
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.